Titre :

Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)

Auteur(s) :

Veziant, Julie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Groupe francophone de Réhabilitation Améliorée après Chirurgie [GRACE]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Bouché, Olivier [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Aparicio, T. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Barret, M. [Auteur]
Université Bordeaux Montaigne [UBM]
El Hajbi, F. [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Lepilliez, V. [Auteur]
Hôpital privé Jean Mermoz [Lyon]
Lesueur, P. [Auteur]
Centre de radiothérapie Guillaume le Conquérant [CGLC]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Maingon, P. [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
CHU Pitié-Salpêtrière [AP-HP]
Pannier, D. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Quero, L. [Auteur]
Ecotaxie, microenvironnement et développement lymphocytaire [EMily (UMR_S_1160 / U1160)]
Raoul, J.L. [Auteur]
Institut Paoli-Calmettes [IPC]
Renaud, F. [Auteur]
Sorbonne Université [SU]
Seitz, J.F. [Auteur]
Service d'oncologie digestive et hépato-gastro-entérologie [Hôpital de la Timone - APHM]
Serre, A.A. [Auteur]
Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] [UNICANCER/ICL]
Vaillant, E. [Auteur]
Institut Pasteur de Lille
Université Lille Nord de France (COMUE)
Vermersch, M. [Auteur]
Centre hospitalier [Valenciennes, Nord]
Voron, T. [Auteur]
Sorbonne Université [SU]
CHU Saint-Antoine [AP-HP]
Tougeron, David [Auteur]
Progression et dissémination cérébrales des cellules tumorales [Prodicet [Poitiers]]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Piessen, Guillaume [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Titre de la revue :

Digestive and Liver Disease

Pagination :

1583-1601

Éditeur :

Elsevier

Date de publication :

2023-12

ISSN :

1590-8658

Mot(s)-clé(s) en anglais :

French clinical practice guidelines
Esophageal cancer
Adenocarcinoma
Squamous cell carcinoma
Chemoradiotherapy
Perioperative chemotherapy
Surgery
Immunotherapy

Discipline(s) HAL :

Sciences du Vivant [q-bio]/Cancer

Résumé en anglais : [en]

Introduction: This document is a summary of the French intergroup guidelines regarding the management of esophageal cancer (EC) published in July 2022, available on the website of the French Society of Gastroenterology ...
Lire la suite >Introduction: This document is a summary of the French intergroup guidelines regarding the management of esophageal cancer (EC) published in July 2022, available on the website of the French Society of Gastroenterology (SNFGE) ( www.tncd.org ). Methods: This collaborative work was conducted under the auspices of several French medical and surgical societies involved in the management of EC. Recommendations were graded in three categories (A, B and C), according to the level of evidence found in the literature until April 2022. Results: EC diagnosis and staging evaluation are mainly based on patient's general condition assessment, endoscopy plus biopsies, TAP CT-scan and 18F FDG-PET. Surgery alone is recommended for early-stage EC, while locally advanced disease ( N + and/or T3-4) is treated with perioperative chemotherapy (FLOT) or preoperative chemoradiation (CROSS regimen) followed by immunotherapy for adenocarcinoma. Preop- erative chemoradiation (CROSS regimen) followed by immunotherapy or definitive chemoradiation with the possibility of organ preservation are the two options for squamous cell carcinoma. Salvage surgery is recommended for incomplete response or recurrence after definitive chemoradiation and should be performed in an expert center. Treatment for metastatic disease is based on systemic therapy including chemotherapy, immunotherapy or combined targeted therapy according to biomarkers testing such as HER2 status, MMR status and PD-L1 expression. Conclusion: These guidelines are intended to provide a personalised therapeutic strategy for daily clinical practice and are subject to ongoing optimization. Each individual case should be discussed by a multidisciplinary team. (c) 2023 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL